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Abstract In the last years several studies have been
performed on migraine; however, only few topics have
changed the clinical practice. Among these, there are
physiopathological insights (e.g., allodynia and gastric
stasis) or therapeutical evidences (e.g., topiramate) that
become very important in the management of migraine and
could clarify the different response to the therapies. The
aim of a training school on headache should be to link
research to practice without transferring contradictory data.
To teach is not only to support notions with simple data: we
think that knowledge has to be used according to the
condition of the patient and the situation in which the
migraineurs live.
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Introduction
Aims of a training school are to support students with
update scientiﬁc information and to prepare new operators
to better face their job. A school must be a link between
research and practice. The importance of new data obtained
from research depends on their reﬂections on daily activity.
In the last years several studies has been performed on
migraine; however, only few topics have changed the
clinical practice. Among these, there are physiopathologi-
cal insights (e.g., allodynia and gastric stasis) or thera-
peutical evidences (e.g., topiramate) that become very
important in the management of migraine and could clarify
the different response to the therapies.
Backgrounds
Cutaneous allodynia (CA) refers to the perception of pain or
discomfort in response to non-noxious thermal and
mechanical stimuli applied to normal skin [1], and is the
clinical manifestationof central sensitization inmigraine [2,
3]. CA is more commonly reported in persons with frequent
headache, long duration of the disorder and transformed
migraine, suggesting that it is the result of repeated sensi-
tization of central pathways over time [4–8]. It has been
suggested that central sensitization may be associated with
neuronal changes impairing efﬁcacy of triptans when used
after 1 h from the onset of migraine attacks [9]. Therefore,
the triptans effectively abort migraine attacks in 93% of
patients prior to development of allodynia, compared with
only 15% in the presence of allodynia [10]. Conversely, the
presence of allodynia does not limit the use of intramuscular
dihydroergotamine [11]. A more recent study suggested that
intravenous administration of ketorolac or naproxen may
effectively terminate migraine attacks, even after the onset




Several studies demonstrated that a gastric stasis is
associated with migraine attacks. In practice, these
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migraine patients with NSAID [13, 14]. Nevertheless, it
has been suggested that gastroparesis is a feature of the
migraine rather than of the attack [15]. Some studies sug-
gested that triptans are effective in reducing migrainous
nausea by central mechanism of action [16, 17].
Efﬁcacy of topiramate (TPM) in the prevention of
migraine is well demonstrated [18, 19]. Last reports focus
their attention on long-term use. Usually, prevention
should last for 3–4 months, although recent evidences, as
well as clinical experience, suggest the possibility of
increased efﬁcacy with use of preventive drugs for longer
periods (up to 6–14 months) [20–22]. Also the frequency
of adverse events was lower in the open label phase than
the double-blind phase. A recent review observed that the
clinical beneﬁt appears to be sustained in patients treated
with TPM over 1 year and that there was no loss of efﬁcacy
over time, even when patients switched from a higher to a
lower dose [23]. These evidences let clinicians able to use
different patterns of therapy, trying to satisfy the needs of
patients with very different dosages and times to treat.
Conclusions
We reported only these few insights from clinical research.
A training school of headache must link research to prac-
tice and does not have to transfer contradictory data. To
teach is not only to support notions with simple data: we
think that knowledge has to be used according to the
condition of the patient and the situation in which the
migraineurs live. Beside this, every teacher has his own
exclusive experience provided by intuition that can be a
good resort to learn something more than simple infor-
mation. It is just this intuition that can suggest to the
researchers new ideas and new strategies to move in new
ﬁelds. In this case a school can achieve its real goal: to
create a two-way relationship between science and daily
practice, creating more efﬁcient ‘‘actors’’ in both ﬁelds.
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